1. Introduction {#sec1}
===============

The severe acute respiratory syndrome coronavirus-2 (Sars-Cov-2) and its associated infection known as COVID-19 have resulted in a global pandemic, accounting for over 4 million cases and more than 300,000 deaths worldwide as of the writing of this article.[@bib1] New York City was one of the epicenters of the pandemic, with nearly 200,000 confirmed cases as of May 16, 2020 and thus it has been an ideal location to study the clinical course associated with the viral infection.[@bib2]

Several studies have described the clinical manifestations associated with COVID-19 infections. The ocular manifestations are nonspecific and can include signs related to conjunctivitis such as hyperemia, chemosis, epiphora, secretions, and eyelid edema.[@bib3], [@bib4], [@bib5] Still, some of these signs may relate to other factors such as immunological responses, external trauma, or exposure keratopathy especially in the intensive care unit (ICU) setting. A recent meta-analysis of 1167 patients found that 1.1% of patients had conjunctivitis at the time of admission, with 3% in patients showing severe systemic manifestations, and 0.7% in those with non-severe cases.[@bib3] The authors found a statistically significant difference between these two categories, where patients with severe infections were 3.4 times more likely to have conjunctivitis.[@bib6] In fact, in some cases conjunctivitis may be the only presenting sign of COVID-19.[@bib7] Still, authors using RT-PCR testing found that only 5.2% of patients were positive for SARS-CoV-2 when using conjunctival samples.[@bib3] Similarly, a meta-analysis demonstrated that 4% of conjunctival PCR samples were positive for infection.[@bib6] Other ophthalmic symptoms of COVID-19 infection include dry eye, blurry vision, and foreign body sensation.[@bib8]

In pediatric patients, conjunctivitis has been reported in association with a COVID-19 related multisystem inflammatory condition with features similar to Kawasaki disease and toxic shock syndrome.[@bib9], [@bib10], [@bib11], [@bib12] On April 27, 2020 the Pediatric Intensive Care Society alerted clinicians about this type of severe COVID-19 infection in children, citing a case report of a 6-month-old-infant.[@bib12] The patient was admitted and diagnosed with classic Kawasaki disease and tested positive for COVID-19, treated per guidelines with intravenous immunoglobulin (IVIG) and high-dose aspirin, and subsequently recovered.[@bib12]

In New York City, the Health Department identified 15 patients aged 2--15 years hospitalized in pediatric ICUs from April 17 to May 1, 2020 with illnesses compatible with typical Kawasaki disease, incomplete Kawasaki disease, and/or shock.[@bib13] More recently on May 15, 2020 the World Health Organization (WHO) published a scientific brief summarizing the current knowledge related to these pediatric patients and a preliminary case definition. The WHO definition for this COVID-19 Kawasaki-like syndrome differs slightly from the commonly used criteria for Kawasaki disease related to children with other viral infections and can be found in [Table 1](#tbl1){ref-type="table"}, along with a comparison of the classic criteria. The definition includes children and adolescents below the age of 19 with several symptoms and signs and a positive COVID-19 test or likely contact with COVID-19 positive individuals.[@bib10]Table 1Diagnostic criteria. Comparison of the WHO definition for COVID-19 Kawasaki-like syndrome to the classic diagnostic criteria used for Kawasaki disease related to other viral infections.Table 1World Health Organization (WHO) Preliminary Case Definition of COVID-19 Kawasaki Syndrome in Children and Adolescents[@bib14]Classic Criteria for Kawasaki Disease Associated with Other Viral Infections[@bib24]**Symptoms**•Fever \>3 days•Fever \>5 days**Signs**At least 2 of the following:•Rash or bilateral non-purulent conjunctivitis or muco-cutaneous inflammatory signs (oral, hands, feet)•Hypotension or shock•Myocardial dysfunction, pericarditis, valvulitis, or coronary abnormalities•Evidence of coagulopathy on laboratory testing•Acute gastrointestinal problems (diarrhea, vomiting, abdominal pain)And:•Elevated inflammatory makers on laboratory testing•No other obvious microbial cause of inflammation•Evidence of COVID-19 infectionAt least 4 of the following clinical signs, not explained by another disease process:•Bilateral conjunctival injection consistent with conjunctivitis•Changes in oropharyngeal mucous membranes, such as injected/and or fissured lips, strawberry tongue, or injected pharynx•Polymorphous rash, non-vesicular•Cervical lymphadenopathy with at least 1 node \>1.5 cm•Changes in extremities, including erythema and/or edema of the hands and feet or periungual desquamation

2. Case report {#sec2}
==============

Herein, we describe the clinical course of an adult patient with COVID-19 and symptoms and signs consistent with a Kawasaki-like syndrome similar to that recently reported in pediatric patients. To our knowledge this report may be the first published case of a COVID-19 related Kawasaki-like syndrome in an adult patient. On May 5, 2020, a forty-five-year-old otherwise healthy male without past ocular history presented with five days of fever, sore throat, diarrhea, eye redness, eyelid swelling, and a diffuse rash including bilateral upper and lower eyelids. On admission he was found to be COVID-19 positive on PCR testing with lymphopenia, severely elevated inflammatory markers including ferritin, CRP, ESR, and D-dimer, and elevated troponin. A transthoracic echocardiogram demonstrated global hypokinesis and a reduced ejection fraction of 40% and CT imaging showed unilateral cervical lymphadenopathy with a lymph node measuring 1.8 cm. In addition, he reported photophobia and swollen eyelids that began at the same time as the aforementioned symptoms. He denied other vision changes including blurry vision and eye pain. External photos exhibiting his periorbital rash involving the upper and lower eyelids, bilateral diffuse conjunctival hyperemia and trace chemosis consistent with non-exudative conjunctivitis, and perioral mucosal involvement are shown in [Fig. 1](#fig1){ref-type="fig"}. On exam, uncorrected near visual acuity was 20/20 bilaterally with bilateral superficial punctate keratitis, symmetric anterior chamber (AC) inflammation with 10--15 cells per high power field, and normal intraocular pressure. Dilated fundus exam was notable only for one small peripheral cotton wool spot in each eye. Given the patient\'s clinical status including the inpatient setting and symptomatic COVID-19 positive status, additional imaging including fundus photos or OCT could not be obtained. The lack of additional ophthalmic testing could be a limitation of this case report.Fig. 1**Initial presentation**.External photos exhibiting the patient\'s periorbital rash involving the upper and lower eyelids, bilateral diffuse conjunctival hyperemia consistent with non-exudative conjunctivitis, and perioral mucosal changes.Fig. 1

A multidisciplinary effort involving dermatology, rheumatology, infectious disease, cardiology, and ophthalmology teams collaborated on the patient\'s care. Punch biopsy of his erythema multiforme-like rash (which has been seen in pediatric Kawasaki disease[@bib14]^,^[@bib15] and COVID-19 patients)[@bib16] showed sparse superficial perivascular infiltrate of lymphocytes with neutrophils and scattered eosinophils, suggestive of toxic shock syndrome. In this case, however, the patient did not demonstrate other shock-like signs such as hypotension. He continued to be febrile during the admission. Testing for myositis, especially given the heliotrope-appearing rash and concern for possible dermatomyositis, including anti-Jo, anti-Ro, and anti-La testing was negative. HIV testing was negative. An exhaustive rheumatologic workup including ANA, RF, anti-CCP, anti-Smith, anti-dsDNA, *p*-ANCA/MPO, c-ANCA/PR3 was also negative. Blood cultures were negative.

Our patient showed many symptoms and signs consistent with previously published ocular manifestations of Kawasaki disease associated with other viral infections.[@bib17], [@bib18], [@bib19], [@bib20], [@bib21] One of these studies, a review of 41 patients, found that conjunctival injection (78%) and AC reaction (19.5%) were the most common ocular features.[@bib17] Furthermore, our patient not only exhibited sufficient criteria for the aforementioned WHO definition for COVID-19 related Kawasaki syndrome, but also the common criteria for Kawasaki disease associated with other viral infections, including persistent fevers, non-exudative conjunctivitis, unilateral cervical adenopathy greater than 1.5 cm, and inflammation of the oral mucosa.[@bib22]^,^[@bib23]

Although this patient tested negative for HIV, prior literature has demonstrated a Kawasaki-like syndrome in HIV positive patients. One study showed that HIV infection can predispose a patient to this syndrome and these cases were particularly associated with severe immunosuppression and a high viral load.[@bib24]

We treated our patient with ophthalmic lubricating therapy in addition to prednisolone acetate 1% eye drops four times daily for his photophobia in the setting of AC inflammation. He was treated systemically with IVIG and an IL-6 inhibitor (tocilizumab) in addition to using a topical triamcinolone ointment for his diffuse rash. His fever resolved and he clinically improved with decreasing inflammatory markers. On repeat ophthalmic examination two weeks later, his vision was stable and his periorbital rash, ocular surface disease, and conjunctival injection all improved ([Fig. 2](#fig2){ref-type="fig"}). His AC reaction had also resolved. We tapered his topical steroid and continued to monitor his exam.Fig. 2**Follow-up examination**.External photos exhibiting the patient\'s improved clinical signs including minimal bilateral periorbital rash and conjunctival hyperemia.Fig. 2

3. Discussion {#sec3}
=============

This case highlights a new manifestation of Kawasaki-like disease in an adult with COVID-19 infection who had numerous anterior segment findings. This coronavirus represents a new clinical entity, and we are learning about its many varied presentations almost daily. The new description of Kawasaki type disease associated with COVID-19 in the pediatric population over the past several months certainly has very serious, and in rare cases, life threatening implications. To our knowledge, this report may be the first case of a Kawasaki-like syndrome in an adult with COVID-19 infection.
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